Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

BICO Group

17.49 SEK

-0.40 %

Less than 1K followers

BICO

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.40 %
+3.00 %
-16.95 %
-10.81 %
-21.92 %
-55.74 %
-74.17 %
-95.40 %
+28.37 %

BICO Group operates in the biotechnology industry and focuses on the development and manufacturing of technologies for cell-based research and medical development. The company's products are aimed at researchers and pharmaceutical companies. The business is global with a main presence in Europe, North America and Asia. BICO Group was founded in 2016 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
1.23B SEK
Turnover
1.63K SEK
Revenue
1.5B
EBIT %
-86.33 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.4
2026

Interim report Q1'26

7.5
2026

General meeting '26

19.8
2026

Interim report Q2'26

All
Webcasts
Press releases
ShowingAll content types
Press release2/20/2026, 12:52 PM

Redeye: BICO (Q4 review): Improving outlook and trades at <1x sales

BICO Group
BICO, Audiocast, Q4'25
Webcast2/18/2026, 9:00 AM

BICO, Audiocast, Q4'25

BICO Group
Regulatory press release2/18/2026, 6:00 AM

Publication of BICO Group AB: Year-end report 2025

BICO Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/4/2026, 6:00 AM

Invitation to the presentation of BICO’s Year-end report 2025

BICO Group
Regulatory press release1/28/2026, 4:12 PM

BICO Group AB (publ) has successfully issued senior secured bonds

BICO Group
Press release1/23/2026, 6:00 AM

BICO company Biosero launches GoSimple™, a standardized automation-ready workcell with selected instruments from Sartorius and Becton, Dickinson and Company (BD)

BICO Group
Regulatory press release12/16/2025, 6:00 AM

Jesper Hagberg appointed as Chief Operations & Digital Officer for BICO Group AB

BICO Group
Regulatory press release12/10/2025, 6:00 AM

Ewa Linsäter appointed as Chief Financial Officer for BICO Group AB

BICO Group
Press release11/14/2025, 11:34 AM

Redeye: BICO (Q3 Review) - A return to organic growth and adjusted EBITDA profitability

BICO Group
BICO, Audiocast, Q3'25
Webcast11/4/2025, 9:00 AM

BICO, Audiocast, Q3'25

BICO Group
Regulatory press release11/4/2025, 6:00 AM

Publication of BICO Group AB: Interim report Q3 2025

BICO Group
Regulatory press release11/3/2025, 5:01 PM

BICO provides preliminary figures for Q3 2025 and announces impairment

BICO Group
Press release10/21/2025, 5:00 AM

Invitation to the presentation of BICO’s Interim report Q3 2025

BICO Group
Regulatory press release10/10/2025, 5:00 AM

BICO Group AB’s Nomination Committee for the 2026 Annual General Meeting

BICO Group
Regulatory press release9/16/2025, 4:28 PM

Maria Rankka appointed Board Chair of BICO Group AB

BICO Group
Press release9/15/2025, 5:00 AM

Fraser McLeod appointed as Managing Director of BICO company Biosero

BICO Group
Regulatory press release9/4/2025, 10:05 PM

BICO company Biosero to develop integrated lab automation solutions to a value of 15.2 MUSD

BICO Group
Press release8/28/2025, 8:34 AM

Redeye: Redeye Initiates Coverage of BICO Group

BICO Group
BICO, Audiocast, Q2'25
Webcast8/19/2025, 8:00 AM

BICO, Audiocast, Q2'25

BICO Group
Regulatory press release8/19/2025, 5:00 AM

Publication of BICO Group AB Interim report January-June 2025

BICO Group
Forum discussions
Let’s revive this thread again. Bico’s 2024 results are out, and after a couple of years in the wilderness, things actually look quite good. Losses have significantly decreased from 2023, and Q4/2024 has been a profitable quarter. Source: https://bico.com/investors/ If anyone is ...
2/21/2025, 9:55 AM
by Karibu
7
Tässä ABG:n tuoreesta rapsasta pääkohdat. Target laskettu 35 SEK (210) ja suositus laskettu HOLD (BUY). Preliminary Q2 figures and credit provision Preliminary Q2 sales were SEK 543m (-9% vs ABGSCe 594m) and EBITDA was SEK -20m (-165% vs ABGSCe SEK 31m). The organic growth was 9%...
7/18/2022, 7:34 AM
by Hasbi
7
This news published in early July hadn’t been posted here yet: Next step in Sartorius partnership finalized: several sub-sales and distribution agreements as well as R&D project agreements have been signed BICO Single Press release BICO enables and automates the life science lab ...
7/19/2023, 10:29 AM
by Warren Noutopöytätarjoilu
6
Riskillä lisäilin isosti kun käytiin kolmenkympin alapuolella, heinäkuun kurssilasku tuntui niin yliampuvalta. Aika hyvä raportti ja tekemisen suunta näyttää taas erittäin hyvältä. Tätä kirjoittaessa +38% reaktio rapsaan BICO - The Bio Convergence Company Single Press release
11/9/2022, 8:58 AM
by jepukka666
6
Bico heräilee koomasta pyrähdyksittäin. Tätä kirjoitettaessa on kaikkien aikojen yhden päivän kurssinousu. Eli Sartorius ostaa 10% siivun Bicosta ja ne ovat uusia osakkeita, jotka liudentavat omistusta. Paradoksaalisesti tämä osakeanti aiheutti osakkeen kasvupyrähdyksen. On ainakin...
12/9/2022, 1:17 PM
by Karibu
5
Ja takaisin kanveesiin BICO Group AB (publ) today announces the decision to impair goodwill in Ginolis totaling SEK 625 million, ahead of the year-end report 2022 to be published on 22 February 2023. BICO - The Bio Convergence Company Single Press release BICO skapar framtiden fö...
2/21/2023, 7:07 PM
by Pohjolan Eka
3
Bico Group Audiocast Q3’25: Inderes BICO, Audiocast, Q3'25 - Inderes Time: 2025-11-04 10:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference
11/4/2025, 12:16 PM
by Isa Hudd
2
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.